SEOUL, South Korea, July 29, 2024 /PRNewswire/ -- Daewoong Pharmaceutical (Co-CEOs Chang-Jae Lee and Seongsoo Park) announced a significant milestone in the development of 'Bersiporocin (DWN12088)', a first-in-class PRS inhibitor for idiopathic pulmonary fibrosis (IPF), has taken a significant step towards commercialization by demonstrating positive safety data from the Phase 2 clinical trial.
ORLANDO, Fla., June 19, 2024 /PRNewswire/ -- Daewoong Pharmaceutical (CEOs Chang-jae Lee and Seongsoo Park) announced that it will present the pooled analysis results of the Phase 3 clinical trials for Enavogliflozin at the 84th American Diabetes Association conference in Orlando, USA, from June 21 to 24. These results showcase Enavogliflozin's efficacy and safety in patients with mild renal impairment who struggle with blood glucose control.
SEOUL, South Korea, Feb. 6, 2024 /PRNewswire/ -- Daewoong Pharmaceutical (KRX: 069620.KS), a global pharmaceutical company located in Seoul, announced its marvelous financial results for 2023.
Daewoong's Bersiporocin Receives 'Orphan Drug Designation' in Europe
HanAll, Daewoong and NurrOn to Showcase Ongoing Parkinson's Disease Program
Zydus Worldwide DMCC, a wholly owned subsidiary of Zydus Lifesciences Ltd and Daewoong Pharmaceutical announced that they have entered into an exclusive licensing agreement to co-develop and commercialize Leuprolide Acetate for Depot Suspension in six dosage strengths for the United States (US) market.
SEOUL, South Korea, Nov. 6, 2023 /PRNewswire/ -- Daewoong Pharmaceutical (CEOs Seng-Ho Jeon and Chang-Jae Lee) announced on the 6th that it will commence full-scale development of an obesity treatment utilizing a microneedle patch loaded with GLP-1 (Glucagon-like peptide-1) analogues. The microneedle technology, which involves applying an ultra-small 1cm² patch to the arm or abdomen, represents an advanced formulation that significantly enhances user convenience over traditional obesity treatments. Daewoong Pharmaceutical is set to initiate Phase 1 clinical trials early next year, with the goal of commercializing the product by 2028.
SEOUL, South Korea, Nov. 1, 2023 /PRNewswire/ -- Daewoong Pharmaceutical (KRX: 069620.KS) is pleased to announce its financial results for the third quarter of 2023. Demonstrating a consistent growth trajectory, the company achieved stand-alone sales of KRW 303 billion and an impressive operating profit of KRW 34.2 billion.
SEOUL, South Korea, Oct. 19, 2023 /PRNewswire/ -- Daewoong Pharmaceutical is thrilled to announce its participation in CPHI Worldwide 2023, one of the world's premier pharmaceutical industry exhibitions. The event is scheduled to take place from the 24th to the 26th of October at Fira Barcelona Gran Via, Spain.
ROCKVILLE, Md. and SEOUL, South Korea, Oct. 12, 2023 /PRNewswire/ -- HanAll Biopharma (KRX: 009420. KS), Daewoong Pharmaceutical (KRX: 069620.KS), and NurrOn Pharmaceuticals marked a major milestone by dosing the first human healthy participant in their Phase 1 clinical trial, assessing HL192 (NurrOn designation code: ATH-399A) which is being developed for the treatment of Parkinson's disease (PD).